We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ribociclib

News List

New Indication Approval for Ribociclib: A Game Changer for CDK4/6 Inhibitors Yefenghong
October 18, 2024
Recently, the FDA officially approved Novartis's ribociclib, in combination with aromatase inhibitors (AI), for the adjuvant treatment of hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)
ASCO: Survival Up With Ribociclib in Advanced Breast Cancer drugs
June 05, 2019
Survival Up With Ribociclib in Advanced Breast Cancer.
Ribociclib could be used to treat glioblastoma europeanpharmaceuticalreview
November 21, 2018
Ribociclib, a drug approved to treat breast cancer, could be used to treat one of the deadliest forms of cancer – glioblastoma…
Novartis receives EU approval for ribociclib europeanpharmaceuticalreview
August 25, 2017
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer